Mrs. Jacqueline Ann Dye, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 6752 Rolling Meadow Dr, Davisburg, MI 48350 Phone: 248-328-0902 |
News Archive
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Chronic lymphocytic leukemia (CLL) is the most common form of blood cancer (leukemia) in the Western world, affecting approximately 1.2% of all cancer patients.
In a recent paper published in PLOS One, Soumya Chatterjee, M.D., assistant professor of infectious diseases, allergy and immunology at Saint Louis University, presents data to show that a focus on high-risk tuberculosis patients may be the answer to stalled progress in stamping out the illness in the United States.
The government watchdog organization also found that more problems could emerge in the upcoming enrollment season. Investigators suggested implementation of a cost-control plan and improved oversight procedures, among other steps.
› Verified 5 days ago